Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.

Rappo U, Gonzalez PL, Puttagunta S, Akinapelli K, Keyloun K, Gillard P, Liu Y, Dunne MW.

J Glob Antimicrob Resist. 2019 Feb 20;17:60-65. doi: 10.1016/j.jgar.2019.02.007. [Epub ahead of print]

2.

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.

Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, Suen A, Mas Casullo V, Melnick D, Miceli R, Kovacevic M, De Bock G, Dunne MW.

Open Forum Infect Dis. 2018 Dec 10;6(1):ofy331. doi: 10.1093/ofid/ofy331. eCollection 2019 Jan.

3.

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.

Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW.

Drugs Context. 2018 Dec 11;7:212559. doi: 10.7573/dic.212559. eCollection 2018.

4.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

PMID:
30397056
5.

Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.

Gonzalez D, Bradley JS, Blumer J, Yogev R, Watt KM, James LP, Palazzi DL, Bhatt-Mehta V, Sullivan JE, Zhang L, Murphy J, Ussery XT, Puttagunta S, Dunne MW, Cohen-Wolkowiez M.

Pediatr Infect Dis J. 2017 Jul;36(7):645-653. doi: 10.1097/INF.0000000000001538.

6.

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.

Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S.

Drug Saf. 2016 Feb;39(2):147-57. doi: 10.1007/s40264-015-0374-9. Review.

7.

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.

Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J.

Clin Infect Dis. 2016 Mar 1;62(5):545-51. doi: 10.1093/cid/civ982. Epub 2015 Nov 26.

8.

Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.

Barnea Y, Lerner A, Aizic A, Navon-Venezia S, Rachi E, Dunne MW, Puttagunta S, Carmeli Y.

J Antimicrob Chemother. 2016 Feb;71(2):460-3. doi: 10.1093/jac/dkv357. Epub 2015 Oct 30.

PMID:
26518048
9.

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects.

Scoble PJ, Owens RC Jr, Puttagunta S, Yen M, Dunne MW.

Clin Drug Investig. 2015 Dec;35(12):785-93. doi: 10.1007/s40261-015-0340-4.

10.

In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program.

McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW.

Antimicrob Agents Chemother. 2015 Aug;59(8):5007-9. doi: 10.1128/AAC.00274-15. Epub 2015 May 18.

11.

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.

Dunne MW, Sahm D, Puttagunta S.

Ann Clin Microbiol Antimicrob. 2015 Apr 2;14:19. doi: 10.1186/s12941-015-0081-5.

12.

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.

Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J.

Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. doi: 10.1128/AAC.04550-14. Epub 2015 Jan 5.

13.

Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age.

Bradley JS, Puttagunta S, Rubino CM, Blumer JL, Dunne M, Sullivan JE.

Pediatr Infect Dis J. 2015 Jul;34(7):748-52. doi: 10.1097/INF.0000000000000646.

PMID:
25551831
14.

The role of elastography in evaluating thyroid nodules: a literature review and meta-analysis.

Veer V, Puttagunta S.

Eur Arch Otorhinolaryngol. 2015 Aug;272(8):1845-55. doi: 10.1007/s00405-014-3155-7. Epub 2014 Jul 6. Review.

PMID:
24997982
15.

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW.

N Engl J Med. 2014 Jun 5;370(23):2169-79. doi: 10.1056/NEJMoa1310480.

16.

A validated LC-MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study.

Shaik RP, Puttagunta SB, Kothapalli CB, Awen BZS, Challa BR.

J Pharm Anal. 2013 Dec;3(6):489-499. doi: 10.1016/j.jpha.2013.04.005. Epub 2013 May 24.

18.

The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patients.

Ledizet M, Murray TS, Puttagunta S, Slade MD, Quagliarello VJ, Kazmierczak BI.

PLoS One. 2012;7(11):e49578. doi: 10.1371/journal.pone.0049578. Epub 2012 Nov 12.

19.

An analysis of intraoperative versus post-operative dosimetry with CT, CT-MRI fusion and XMR for the evaluation of permanent prostate brachytherapy implants.

Acher P, Puttagunta S, Rhode K, Morris S, Kinsella J, Gaya A, Dasgupta P, Deehan C, Beaney R, Popert R, Keevil S.

Radiother Oncol. 2010 Aug;96(2):166-71. doi: 10.1016/j.radonc.2010.06.003. Epub 2010 Jul 6.

PMID:
20615565
20.

Cardiac manifestations of HIV.

Sadigh M, Puttagunta S.

Front Biosci. 2003 May 1;8:s305-13. Review.

PMID:
12700114
21.

Desmosomal cadherin binding domains of plakoglobin.

Witcher LL, Collins R, Puttagunta S, Mechanic SE, Munson M, Gumbiner B, Cowin P.

J Biol Chem. 1996 May 3;271(18):10904-9.

22.

Supplemental Content

Loading ...
Support Center